Skip to main content

Table 4 Multivariable analysis on baseline plasma NfL levels with cognitive and motor outcomes in PD patients over time

From: Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson’s disease

OutcomesMDS-UPDRS Part III (Motor)aMMSE
β (95% CI)bp valueβ (95% CI)p value
NfL (PIGD)9.73 (3.65, 15.81)0.002− 2.09 (−3.90, − 0.28)0.024
NfL (TD)−3.90 (− 9.36, 1.57)0.1610.50 (− 1.14, 2.13)0.549
NfL x Motor Subtype13.6 (6.16, 21.1)< 0.001−2.59 (− 4.81, − 0.36)0.023
Age0.10 (− 0.12, 0.32)0.385−0.08 (− 0.14, − 0.01)0.025
Gender−2.75 (− 5.84, 0.35)0.081−0.09 (− 1.01, 0.83)0.839
Disease duration−0.75 (− 2.43, 0.93)0.3790.17 (− 0.34, 0.69)0.506
  1. Abbreviations: PD Parkinson’s Disease; TD Tremor-Dominant; PIGD Postural Instability Gait Disorder; MDS-UPDRS Movement Disorder Society Unified Parkinson’s Disease Rating Scale; MMSE Mini Mental State Examination; CI Confidence Interval; NfL Neurofilament light chain protein
  2. a MDS-UPDRS Part III (Motor) and MMSE scores of PD patients over 2 years are the outcome variables
  3. b Beta coefficient (and 95% CI) of Ln-NfL level; Linear mixed models adjusted for age, sex, disease duration and NfL x motor subtype interaction